Literature DB >> 22948744

Of mice and men: the need for humanized mouse models to study human IgG activity in vivo.

Anja Lux1, Falk Nimmerjahn.   

Abstract

Antibodies of the IgG isotype have a variety of pro- and anti-inflammatory effector functions, making them attractive platforms for the development of novel therapeutic approaches. Animal model systems have been invaluable to the understanding of the underlying mechanisms of IgG activity. However, differences in the IgG subclasses and Fc receptors responsible for mediating IgG-dependent effector functions, even between such closely related species as humans and monkeys, make it difficult to predict the activity of human IgG in vivo. This review will focus on currently available animal model systems used to study human IgG activity and will propose novel model systems that might enable us to obtain a closer look at the molecular and cellular mechanisms underlying human IgG activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948744     DOI: 10.1007/s10875-012-9782-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  21 in total

1.  IgEb immune complexes activate macrophages through FcgammaRIV binding.

Authors:  Masayuki Hirano; Randall S Davis; W David Fine; Shugo Nakamura; Kentaro Shimizu; Hirokazu Yagi; Koichi Kato; Robert P Stephan; Max D Cooper
Journal:  Nat Immunol       Date:  2007-06-10       Impact factor: 25.606

2.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

Authors:  Pierre Bruhns; Bruno Iannascoli; Patrick England; David A Mancardi; Nadine Fernandez; Sylvie Jorieux; Marc Daëron
Journal:  Blood       Date:  2008-11-18       Impact factor: 22.113

3.  Mouse model recapitulating human Fcγ receptor structural and functional diversity.

Authors:  Patrick Smith; David J DiLillo; Stylianos Bournazos; Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

4.  Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Authors:  Jeffrey B Stavenhagen; Sergey Gorlatov; Nadine Tuaillon; Christopher T Rankin; Hua Li; Stephen Burke; Ling Huang; Sujata Vijh; Syd Johnson; Ezio Bonvini; Scott Koenig
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

5.  Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura.

Authors:  Willemijn B Breunis; Edwin van Mirre; Marrie Bruin; Judy Geissler; Martin de Boer; Marjolein Peters; Dirk Roos; Masja de Haas; Harry R Koene; Taco W Kuijpers
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 6.  The role of FcgammaRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Caroline Tan Sardjono; Patricia L Mottram; P Mark Hogarth
Journal:  Immunol Cell Biol       Date:  2003-10       Impact factor: 5.126

7.  Depletion of B cells in murine lupus: efficacy and resistance.

Authors:  Anupama Ahuja; Jonathan Shupe; Robert Dunn; Michael Kashgarian; Marilyn R Kehry; Mark J Shlomchik
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

8.  Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.

Authors:  Akira Okazaki; Emi Shoji-Hosaka; Kazuyasu Nakamura; Masako Wakitani; Kazuhisa Uchida; Shingo Kakita; Kouhei Tsumoto; Izumi Kumagai; Kenya Shitara
Journal:  J Mol Biol       Date:  2004-03-05       Impact factor: 5.469

Review 9.  Novel human antibody therapeutics: the age of the Umabs.

Authors:  Sigrid R Ruuls; Jeroen J Lammerts van Bueren; Jan G J van de Winkel; Paul W H I Parren
Journal:  Biotechnol J       Date:  2008-10       Impact factor: 4.677

10.  Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice.

Authors:  M Li; U Wirthmueller; J V Ravetch
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  20 in total

1.  Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

Authors:  Zelda Euler; Galit Alter
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

2.  Immune complexes regulate bone metabolism through FcRγ signalling.

Authors:  Takako Negishi-Koga; Hans-Jürgen Gober; Eriko Sumiya; Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Ayako Suematsu; Tomomi Suda; Kojiro Sato; Toshiyuki Takai; Hiroshi Takayanagi
Journal:  Nat Commun       Date:  2015-03-31       Impact factor: 14.919

3.  LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection.

Authors:  Falk Nimmerjahn; Anja Lux
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-05       Impact factor: 11.205

Review 4.  Animal models in HIV-1 protection and therapy.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

Review 5.  N-Glycosylation and Inflammation; the Not-So-Sweet Relation.

Authors:  Barbara Radovani; Ivan Gudelj
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

6.  Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Authors:  J M Vicencio; R Evans; R Green; Z An; J Deng; C Treacy; R Mustapha; J Monypenny; C Costoya; K Lawler; K Ng; K De-Souza; O Coban; V Gomez; J Clancy; S H Chen; A Chalk; F Wong; P Gordon; C Savage; C Gomes; T Pan; G Alfano; L Dolcetti; J N E Chan; F Flores-Borja; P R Barber; G Weitsman; D Sosnowska; E Capone; S Iacobelli; D Hochhauser; J A Hartley; M Parsons; J N Arnold; S Ameer-Beg; S A Quezada; Y Yarden; G Sala; T Ng
Journal:  Cell Death Dis       Date:  2022-03-28       Impact factor: 9.685

7.  Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.

Authors:  Yuki Iwayanagi; Tomoyuki Igawa; Atsuhiko Maeda; Kenta Haraya; Naoko A Wada; Norihito Shibahara; Ken Ohmine; Takeru Nambu; Genki Nakamura; Futa Mimoto; Hitoshi Katada; Shunsuke Ito; Tatsuhiko Tachibana; Kou-ichi Jishage; Kunihiro Hattori
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

8.  Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy.

Authors:  Katja Klausz; Michael Cieker; Christian Kellner; Thies Rösner; Anna Otte; Steffen Krohn; Anja Lux; Falk Nimmerjahn; Thomas Valerius; Martin Gramatzki; Matthias Peipp
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 9.  Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye.

Authors:  Angela S W Tjon; Rogier van Gent; Teunis B Geijtenbeek; Jaap Kwekkeboom
Journal:  Front Immunol       Date:  2015-04-28       Impact factor: 7.561

Review 10.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy.

Authors:  Melissa D Landis; Brian D Lehmann; Jennifer A Pietenpol; Jenny C Chang
Journal:  Breast Cancer Res       Date:  2013-01-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.